The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/22/2015 |
| Start Date: | June 2015 |
| End Date: | September 2015 |
| Contact: | Toll Free Number |
| Phone: | 1-888-577-8839 |
A Study to Evaluate the Influence of Metal Cation-Containing Antacids on MK-0518 Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen
In order to define the safe windows for co-dosing of metal-cation antacids with once daily
administered raltegravir, this study will evaluate the effect of both calcium carbonate and
magnesium/aluminum hydroxide antacids on the pharmacokinetics of raltegravir, due to dosage
of 1200 mg raltegravir in HIV-infected participants already taking 400 mg raltegravir twice
daily as part of their HIV treatment regimen.
administered raltegravir, this study will evaluate the effect of both calcium carbonate and
magnesium/aluminum hydroxide antacids on the pharmacokinetics of raltegravir, due to dosage
of 1200 mg raltegravir in HIV-infected participants already taking 400 mg raltegravir twice
daily as part of their HIV treatment regimen.
Inclusion Criteria:
- Is HIV positive
- Is on a stable raltegravir-containing (400 mg every 12hr) antiretroviral (ARV)
regimen for at least 1 month prior to study entry, with no changes, including dose
adjustments; and agrees to maintain their current ARV therapy throughout the study.
- Is non-pregnant and non-breast feeding female, or female of non-reproductive
potential
- Has a Body Mass Index (BMI) =< 32 kg/m^2
Exclusion Criteria:
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,
hematological, hepatic, immunological, renal, respiratory, genitourinary or major
neurological (including stroke and chronic seizures) abnormalities or diseases
(excluding HIV)
- Has a history of gastric bypass surgery
- Has a history of cancer (malignancy)
- Has a history of chronic diarrhea within approximately 3 months prior to the
pre-trial visit
- Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex
allergy), or has had an anaphylactic reaction or significant intolerability to
prescription or non-prescription drugs or food
- Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within
4 weeks prior to the pre-trial visit
- Has participated in another investigational trial within 4 weeks prior to the
pre-trial visit
- Is currently taking rifampin or atazanavir or is unable to refrain from the use of 1)
any proton pump inhibitor from two weeks prior to the study through the completion of
Period 4, and 2) any H2-blockers, over-the-counter antacids, calcium supplements or
multivitamins from one week prior to the study through the completion of Period 4
- Consumes greater than 3 glasses of alcoholic beverages or distilled spirits per day
- Consumes greater than 6 servings of coffee, tea, cola, energy-drinks, or other
caffeinated beverages per day
- Is currently a regular user (including "recreational use") of any illicit drugs or
has a history of drug (including alcohol) abuse within approximately 6 months of
screening
We found this trial at
1
site
Click here to add this to my saved trials
